Navigation Links
Preclinical Studies Show Promise for Novel Antibody Therapy to Treat Acute Myeloid Leukemia (AML)
Date:12/10/2007

Unique monoclonal antibody successfully targets human leukemic stem cells

ATLANTA, Dec. 10 /PRNewswire/ -- CSL Limited, Australia's leading biopharmaceutical company, has today presented data at the American Society of Hematology (ASH) 49th annual meeting, which demonstrate the promising pre-clinical activity of a novel monoclonal antibody, in the potential treatment of acute myeloid leukemia (AML).

AML is an aggressive cancer of white blood cells and most commonly occurs in adults. It is usually treated with chemotherapy but the cure rate in adults is only about 30%. About 9,000 deaths from AML occur each year in the United States(1). The novel antibody specifically targets the "core cell" of AML, called the leukemic stem cell (LSC) which was first identified in the laboratory of Professor John Dick, one of the key authors of the study(2). It is currently thought that the resistance of leukemic stem cells to chemotherapy is a major reason for the inability to cure most AML, and that improving the outlook for patients with AML will require elimination of these cells.

The antibody used in the research, called 7G3, was first created by Dr Angel Lopez at the Hanson Centre for Cancer Research in Adelaide, South Australia. It hones in on CD123 (IL-3 receptor alpha chain) on the surface of the LSC, blocking its function, growth and survival. CD123 is found on the surface of normal blood stem cells much less frequently, and 7G3 should therefore have no effect on normal blood cell development.

The research presented at the ASH meeting by key investigator Associate Professor Richard Lock of Children's Cancer Institute Australia for Medical Research in Sydney, describes the results of treatment with 7G3 of irradiated immune-deficient mice with AML.

Two central experiments were undertaken; firstly human AML stem cells were treated with 7G3 and then injected into the mice, which were compared with a control group of mice injected with untr
'/>"/>

SOURCE CSL Limited
Copyright©2007 PR Newswire.
All rights reserved

Page: 1 2 3

Related medicine technology :

1. Quark Pharmaceuticals, Inc. Presented Positive Preclinical Results of Systemic RNAi Compound for Acute Renal Failure (ARF)
2. Lpath Demonstrates Preclinical Efficacy of Lpathomab(TM) and Initiates Humanization Process
3. Siemens Preclinical Imaging System Helps The Methodist Hospital in Houston Further Its Research Mission
4. Anadys Pharmaceuticals Presents Preclinical Results on ANA598, a Non-Nucleoside Inhibitor of the NS5B Polymerase, at the 14th International Symposium on Hepatitis C Virus and Related Viruses
5. NicOx and Ferrer Present Promising Clinical and Preclinical Results in Dermatology
6. Isis Reports Preclinical Data Supporting Liver Safety of ISIS 301012
7. Preclinical Data on Lead MEK Inhibitor, RDEA119, to be Presented at the 2007 AACR-NCI-EORTC International Conference on Molecular Targets and Cancer Therapeutics
8. KineMed Presents Preclinical Data for Investigational Agent Demonstrating Neurogenesis and Confirming Improvements in Behavioral Model
9. Tezampanel, TorreyPines Therapeutics Lead Compound, Reduced Muscle Spasticity and Rigidity in Preclinical Study Conducted at University of California, San Diego
10. Telik Announces Presentation of Preclinical Data on Dual Inhibitors of Aurora Kinases and VEGFR2
11. CorNova Preclinical Results of Valecor Platinum(TM) Coronary Stent Studies Presented at TCT 2007 Conference
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:1/15/2014)...  Valeant Pharmaceuticals International, Inc. (NYSE: VRX ... under the Hart-Scott-Rodino Antitrust Improvements Act of 1976 ("HSR") ... its indirect wholly-owned subsidiary, Sapphire Subsidiary Corp. ("Purchaser"), for ... Solta Medical, Inc. (NASDAQ: SLTM ) ("Solta") ...
(Date:1/15/2014)... 15, 2014  Zafgen, Inc., a leading biopharmaceutical company ... obese patients, today announced initial results from its ... of methionine aminopeptidase 2 (MetAP2), in patients with ... obesity.  These results showed improvements in body weight, ...
(Date:1/14/2014)... Corporation (Nasdaq: LMNX ) today announced that it ... on Monday, February 3, 2014. A press release announcing the ... (Logo: http://photos.prnewswire.com/prnh/20100104/LUMINEXLOGO ) Management ... and financial results for the fourth quarter and twelve months ...
Breaking Medicine Technology:Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 2Valeant Pharmaceuticals Announces Receipt Of Antitrust Clearance For Its Previously Announced Acquisition Of Solta Medical, Inc. 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 2Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 3Zafgen Announces Initial Results from Phase 2a Study of Beloranib in Patients with Prader-Willi Syndrome 4Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/24/2014)... An Oregon State University researcher has found a relationship ... symptoms of autism spectrum disorder in very young children. ... first to show a direct relationship between motor skills ... gross motor skills should be included in treatment plans ... assistant professor in OSU,s College of Public Health and ...
(Date:4/24/2014)... caused the first flu pandemic in the 21st century. ... more than 50 people in the country. Since 2011 ... (winter/spring seasons). , Infections with influenza pH1N1 virus ... Organization has recommended Tamiflu for treatment of patients with ... is that it targets viral proteins which mutate quickly ...
(Date:4/23/2014)... Hospital (MGH) investigators may lead to greater availability and ... problem use of fecal material from healthy donors ... difficile ( C. difficile ) bacteria. In ... Clinical Infectious Diseases , the researchers report that use ... patients was as successful in curing recurrent C. ...
(Date:4/23/2014)... April 24, 2014 Pregnant immigrants from Sub-Saharan ... increased monitoring during pregnancy, according to new research ... today in the British Journal of Obstetrics ... and eclampsia rates among immigrants and native-born women ... (Ontario), Denmark, Sweden, Spain (Catalonia and Valencia) and ...
(Date:4/23/2014)... Spokane have developed a new way to detect ... the wheel. , Their recently patented technology is ... in drowsy driversand offers an affordable and more ... detection systems. , Van Dongen"Video-based systems that use ... out of its lane are cumbersome and expensive," ...
Breaking Medicine News(10 mins):Health News:Motor skill deficiencies linked to autism severity in new research 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 2Health News:Use of frozen material for fecal transplant successfully treats C. difficile infection 3Health News:Pregnancy complications may be more common in immigrants from certain regions 2Health News:WSU innovation improves drowsy driver detection 2
... Ben Cousins broke his silence for the first time. Since his ... has indeed a problem of substance abuse. ,He revealed ... the past months. He was being treated for a number of ... did not disclose the name of the drug that he had ...
... a doc, there is a woman; much like the association between a ... ,Some Older men need to be goaded to see a doctor, ... could be a wife, daughter or even a female friend. ... years visit a doctor only after being coaxed and cajoled into seeing ...
... of the public health system in the US keeps tumbling out ... adults with serious mental illness and treated in public systems ... gap has widened since the early '90s when major mental disorders ... going in the wrong direction and have to change course," says ...
... the bottle is not funny. Infact their love for the ... overburdened by the fallout of the binge drinking culture ... become a trend evident among all age groups, class, boundaries ... doom for Australia in the next 20 years. Many Australians ...
... easy access to alcohol-based handrubs can improve hygiene in ... Access journal Critical Care suggests. ,Good ... the spread of infections within hospitals. Alcohol-based handrubs are ... amongst hospital staff remains low. ,One of ...
... a long period of time may decrease brain volume, according ... of Neurology's 59th Annual Meeting in Boston, April 28 ... scans of 1,839 people from the Framingham Offspring study, ages ... low drinkers (one to seven drinks per week), moderate drinkers ...
Cached Medicine News:Health News:Cousins Recovering from His Substance Abuse Problem 2Health News:Major Mental Disorders Cut Life Span by Ten to Fifteen Years 2Health News:Drinking Heavy Amounts of Alcohol Shrinks Your Brain 2
MBP's equivalent to the "Universal Yellow" tip, this 200 L tip utilizes a MicroPoint design for accurate sample handling. 10 L Ref. mark....
... an immunometric ('sandwich') EIA for the ... serum or plasma. LH in the ... anti-LH antibodies directed at different epitopes. ... particles and the other is labelled ...
... is a glycoprotein secreted by the anterior ... TSH, the intact LH molecule is a ... glycoproteins all have homologous alpha-subunits, however each ... and FSH production and secretion are stimulated ...
Microwell-EIA for the detection of GAD Autoantibody....
Medicine Products: